Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DDRD2HRH1HTR2AHTR2CSLC6A2
The experimentally established mechanism targets of Trimipramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 7/20 | 1.00 |
| ▸ | SLC6A2 known ✓ | P23975 | 6/20 | 1.00 |
| ▸ | HRH1 known ✓ | P35367 | 6/20 | 0.54 |
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 0.54 |
| ▸ | HTR2A known ✓ | P28223 | 4/20 | 0.54 |
| ▸ | HTR2C known ✓ | P28335 | 4/20 | 0.54 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 9/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 7/20 | 1.00 |
| ▸ | DRD3 | P35462 | 7/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 7/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 6/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | HTR1A | P08908 | 5/20 | 1.00 |
| ▸ | DRD1 | P21728 | 5/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 5/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trimipramine SCHEMBL29373768 | 1.00 | SLC6A4 (1.00) | SLC6A4CHRM1ADRA1ADRD3KCNH2 | |
| Trimipramine SCHEMBL117756 | 1.00 | SLC6A4 (1.00) | SLC6A4CHRM1ADRA1ADRD3KCNH2 | |
| Trimipramine SCHEMBL5494378 | 1.00 | SLC6A4 (1.00) | SLC6A4CHRM1ADRA1ADRD3KCNH2 | |
| Trimipramine SCHEMBL4081184 | 0.98 | SLC6A4 (0.97) | SLC6A4CHRM1ADRA1ADRD3KCNH2 | |
| Trimipramine SCHEMBL30533075 | 0.98 | SLC6A4 (0.97) | SLC6A4CHRM1ADRA1ADRD3KCNH2 | |
| Trimipramine SCHEMBL7597041 | 0.98 | SLC6A4 (0.97) | SLC6A4CHRM1ADRA1ADRD3KCNH2 | |
| Trimipramine SCHEMBL29564386 | 0.91 | SLC6A4 (0.83) | SLC6A4CHRM1ADRA1ADRD3KCNH2 | |
| Trimipramine SCHEMBL6511858 | 0.90 | CHRM1 (0.82) | SLC6A4CHRM1ADRA1ADRD3KCNH2 | |
| Trimipramine SCHEMBL6511859 | 0.90 | CHRM1 (0.82) | SLC6A4CHRM1ADRA1ADRD3KCNH2 | |
| SCHEMBL2615203 | 0.89 | LMNA (0.80) | SLC6A4CHRM1ADRA1ADRD3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 21142 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260108493-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | CAAMTECH, INC. (US) | 2026-04-23 | — | — | US | claimed |
| EP-4706649-A1 | USE OF ADRENALIN FOR THE TREATMENT OF SHOCKS | BIOPROJET (FR) | 2026-03-11 | — | — | EP | claimed |
| US-12550885-B2 | Red blood cell storage solutions, solution additives, and methods for improving the storage of red blood cells | UNIVERSITY OF CINCINNATI (US) | 2026-02-17 | — | — | US | claimed |
| US-12544385-B2 | Combination drug therapies for CNS disorders | JAVED MOHAMMAD (US) | 2026-02-10 | — | — | US | claimed |
| US-20260034106-A1 | Macrocyclic ligands for FK506-binding proteins for treatment of diseases with improved characteristics | UNIV DARMSTADT TECH (DE) | 2026-02-05 | — | — | US | claimed |
| EP-0386117-A1 | TREATING PREMENSTRUAL OR LATE LUTEAL PHASE SYNDROME | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1990-09-12 | — | — | EP | claimed |
| EP-0383835-A1 | SURFACE-ACTIVE POLYSILOXANES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1990-08-29 | — | — | EP | claimed |
| WO-1990004387-A2 | COMPOSITIONS FOR TREATING TOBACCO WITHDRAWAL SYMPTOMS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1990-05-03 | — | — | WO | claimed |
| US-4910015-A | Crosslinked polymer of polyethylene oxide and glycidoxypropylsiloxane | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1990-03-20 | — | — | US | claimed |
| EP-0174342-B1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES | UNIVERSITY OF FLORIDA (US) | 1989-12-20 | — | — | EP | claimed |
| WO-1989003851-A1 | SURFACE-ACTIVE POLYSILOXANES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1989-05-05 | — | — | WO | claimed |
| WO-1989003692-A1 | TREATING PREMENSTRUAL OR LATE LUTEAL PHASE SYNDROME | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1989-05-05 | — | — | WO | claimed |
| US-4788189-A | Method to treat smoking withdrawal symptoms by potentiated central noradrenergic blocking | GLAZER HOWARD I (US) | 1988-11-29 | — | — | US | claimed |
| US-4539199-A | AMINE SALT OF ACRYLIC ACID-ACRYLIC ESTER COPOLYMER | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 1985-09-03 | — | — | US | claimed |
| EP-0089948-B1 | PHARMACEUTICAL COMPOSITIONS | COPPEN, Alec James (GB) | 1985-08-14 | — | — | EP | claimed |